Neumora Therapeutics Initiates Phase 1 Study for NMRA-898

Neumora Therapeutics, Inc. announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study for NMRA-898, a positive allosteric modulator of the M4 muscarinic receptor. This study aims to evaluate the safety, tolerability, and pharmacokinetics of NMRA-898, which has shown potential best-in-class pharmacology in pre-clinical studies. The M4 franchise, which includes NMRA-898 and NMRA-861, targets neuropsychiatric disorders such as schizophrenia, offering a potentially improved therapeutic profile over current treatments. Neumora plans to provide a comprehensive update on the M4 franchise by mid-2026. The company's approach to neuroscience drug development focuses on novel mechanisms of action to address significant unmet medical needs in brain diseases.